Lievano Fabio, Scarazzini Linda, Shen Frank, Duhig James, Jokinen Jeremy
Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, IL, USA.
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):869-874. doi: 10.1002/pds.4241. Epub 2017 Jun 8.
The future of safety science is happening now and has the potential to improve patient outcomes through an evolving approach to benefit-risk assessment. Three building blocks for the future of safety science, cognitive and behavioral systems, medical assessment, and data science, individually and collaboratively advance and modernize the benefit-risk paradigm. Incorporating the patient perspective and patient experiences will help identify tools that are useful in real-world practice. Medical assessment teams will bring together the study of toxicity and toxicogenomics, biomarkers, and special populations to personalize the benefit-risk profile. Personalized benefit-risk profiles for patients will help improve outcomes. Data science and related quantitative sciences such as safety statistics, database integration, technology, and epidemiology will provide new approaches and tools for analysis of safety data as well as more rapid access to insights that benefit patients.
安全科学的未来正在当下发生,并且有潜力通过不断演进的获益-风险评估方法来改善患者预后。安全科学未来的三个基石,即认知与行为系统、医学评估和数据科学,各自以及协同推进并使获益-风险范式现代化。纳入患者视角和患者体验将有助于识别在实际临床实践中有用的工具。医学评估团队将整合毒性与毒理基因组学、生物标志物以及特殊人群的研究,以实现获益-风险概况的个性化。针对患者的个性化获益-风险概况将有助于改善预后。数据科学以及诸如安全统计学、数据库整合、技术和流行病学等相关定量科学,将为安全数据的分析提供新方法和工具,并能更快获取使患者受益的见解。